it’s called a drug indication. A significant amount of drugs approved by the FDA or TGA have a multitude of indications based on their mechanism of action, NYR-BO3 based on its mechanism of action will target a multitude of indications
Zecs your in luck. The treatment of osteoporosis has a direct link to TRPC 8 channel up regulation. So if NYR develop a TRP 8 channel antagonist it can help with the treatment of osteoporosis. The future of NYR with this drug class is bright. But good point you brought up and there is a potential market for further development for TRPC 8 channel inhibitors in the future for the company.
NYR Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)